University of Nebraska Medical Center

DigitalCommons@UNMC
Journal Articles: Pharmacology & Experimental
Neuroscience

Pharmacology & Experimental Neuroscience

2019

A Synthetic Agonist to Vasoactive Intestinal Peptide Receptor-2
Induces Regulatory T Cell Neuroprotective Activities in Models of
Parkinson's Disease
R. Lee Mosley
University of Nebraska Medical Center, Omaha, NE, rlmosley@unmc.edu

Yaman Lu
University of Nebraska Medical Center, yaman.lu@unmc.edu

Katherine E. Olson
University of Nebraska Medical Center, katherine.olson@unmc.edu

Jatin Machhi
University of Nebraska Medical Center, jatin.machhi@unmc.edu

Wenhui Yan
University of Nebraska Medical Center
Follow this and additional works at: https://digitalcommons.unmc.edu/com_pen_articles
See next page for additional authors
Part of the Medical Pharmacology Commons, and the Neurosciences Commons

Recommended Citation
Mosley, R. Lee; Lu, Yaman; Olson, Katherine E.; Machhi, Jatin; Yan, Wenhui; Namminga, Krista L.; Smith,
Jenell R.; Shandler, Scott J.; and Gendelman, Howard, "A Synthetic Agonist to Vasoactive Intestinal
Peptide Receptor-2 Induces Regulatory T Cell Neuroprotective Activities in Models of Parkinson's Disease"
(2019). Journal Articles: Pharmacology & Experimental Neuroscience. 56.
https://digitalcommons.unmc.edu/com_pen_articles/56

This Article is brought to you for free and open access by the Pharmacology & Experimental Neuroscience at
DigitalCommons@UNMC. It has been accepted for inclusion in Journal Articles: Pharmacology & Experimental
Neuroscience by an authorized administrator of DigitalCommons@UNMC. For more information, please contact
digitalcommons@unmc.edu.

Authors
R. Lee Mosley, Yaman Lu, Katherine E. Olson, Jatin Machhi, Wenhui Yan, Krista L. Namminga, Jenell R.
Smith, Scott J. Shandler, and Howard Gendelman

This article is available at DigitalCommons@UNMC: https://digitalcommons.unmc.edu/com_pen_articles/56

ORIGINAL RESEARCH
published: 18 September 2019
doi: 10.3389/fncel.2019.00421

A Synthetic Agonist to Vasoactive
Intestinal Peptide Receptor-2
Induces Regulatory T Cell
Neuroprotective Activities in Models
of Parkinson’s Disease
Edited by:
David Vaudry,
Institut National de la Santé et de la
Recherche Médicale (INSERM),
France
Reviewed by:
Mario Delgado,
Spanish National Research Council
(CSIC), Spain
Nese Tuncel,
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A paradigm shift has emerged in Parkinson’s disease (PD) highlighting the prominent
role of CD4+ Tregs in pathogenesis and treatment. Bench to bedside research,
conducted by others and our own laboratories, advanced a neuroprotective role for
Tregs making pharmacologic transformation of immediate need. Herein, a vasoactive
intestinal peptide receptor-2 (VIPR2) peptide agonist, LBT-3627, was developed as
a neuroprotectant for PD-associated dopaminergic neurodegeneration. Employing
both 6-hydroxydopamine (6-OHDA) and α-synuclein (α-Syn) overexpression models
in rats, the sequential administration of LBT-3627 increased Treg activity without
altering cell numbers both in naïve animals and during progressive nigrostriatal
degeneration. LBT-3627 administration was linked to reductions of inflammatory
microglia, increased survival of dopaminergic neurons, and improved striatal densities.
While α-Syn overexpression resulted in reduced Treg activity, LBT-3627 rescued these
functional deficits. This occurred in a dose-dependent manner closely mimicking
neuroprotection. Taken together, these data provide the basis for the use of VIPR2
agonists as potent therapeutic immune modulating agents to restore Treg activity,
attenuate neuroinflammation, and interdict dopaminergic neurodegeneration in PD. The
data underscore an important role of immunity in PD pathogenesis.
Keywords: neurodegeneration, Parkinson’s disease, vasoactive intestinal peptide, agonist, microglia, regulatory
T cells, alpha-synuclein, 6-hydroxydopamine

INTRODUCTION
Parkinson’s disease (PD) is a progressive degenerative movement disorder characterized by loss of
dopaminergic neurons in the substantia nigra pars compacta (SNpc) and their striatal connections.
No therapies are available to date that alter disease progression. While the etiology of PD remains
enigmatic, misfolded and nitro-oxidation modified alpha synuclein (α-Syn) produce neurotoxic
protofibrils and form Lewy bodies. After extraneuronal release of protofibrils, microglial activation
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and inflammation ensue with consequent neuronal damage
resulting in a cascade of misfolding self-proteins and chronic
inflammation leading to progressive neurodegeneration.
In addition to the innate microglial neuroinflammation
linked to neurodegeneration, peripheral adaptive immunity is
recognized to influence neurodegeneration and, as such, opens
new opportunities for therapy (Ha et al., 2012; Olson et al.,
2015, 2016; Deng and Jin, 2017; Lee et al., 2017; Gelders et al.,
2018). This is highlighted by the key roles that CD4+ T cell
subsets play in the pathobiology of neurodegenerative diseases.
In support of the linkages between immunity and PD, genetic
studies have recently identified links between MHC II and
disease (Kannarkat et al., 2015). Indeed, the delicate balance
between effector T cells (Teffs) and Tregs affect neurodestructive
and neuroprotective outcomes for neurodegenerative activities
(Reynolds et al., 2010; Mosley et al., 2012; Anderson et al.,
2014; Gendelman and Mosley, 2015; Mosley and Gendelman,
2017). Thus, either a minimum frequency or an appropriate
function of peripheral Tregs appear to be vital for central
nervous system (CNS) homeostasis. The number of Tregs or
their activity are diminished in PD, stroke, and amyotrophic
lateral sclerosis (ALS), and as a consequence lead to changes in
the diseased-brain microenvironment with concurrent oxidative
stress, inflammation, and protein misfolding; all serve to augment
or speed neurodegenerative processes (Beers et al., 2011; Rentzos
et al., 2012; Saunders et al., 2012; Henkel et al., 2013; Hu et al.,
2014; Chen et al., 2015; Gendelman et al., 2017; Duffy et al., 2018).
As a result, therapeutic strategies have emerged employing classes
of immunomodulatory agents to promote T cell differentiation
or to increase their baseline activity that lead to attenuation
in both inflammation and oxidative stress that emerge during
disease (ClinicalTrials.gov Identifier: NCT03790670) (RomeroRamos et al., 2014; Gendelman et al., 2017; Kustrimovic et al.,
2018; Solleiro-Villavicencio and Rivas-Arancibia, 2018).
One Treg-promoting agent is vasoactive intestinal peptide
(VIP), a 28-amino acid polypeptide with pleiotropic activities
that also serves as a neurotransmitter for central and autonomic
nervous systems (Said, 2007). Pleiotropic activities for VIP
include effects on vasodilation, secretion, circadian rhythm,
memory recall, and inflammation through activation of specific
class B GPCRs, namely VIPR1 (VPAC1) and VIPR2 (VPAC2),
as well as with the lower affinity pituitary adenylate cyclase
activating polypeptide 1 receptor type 1 (ADCYAP1R1 or PAC1)
(Said, 2007; Vosko et al., 2007; Gomariz et al., 2010; Waschek,
2013; Fan et al., 2015; Kamigaki and Dan, 2017). VIP profoundly
affects innate and adaptive immunity (Delgado and Ganea, 2013),
and in models of autoimmunity exerts immune modulatory
activities. VIP treatment strategies for rheumatoid arthritis,
type I diabetes, Sjögren’s disease, inflammatory bowel disease,
experimental autoimmune encephalomyelitis, and autoimmune
uveitis are in development (Delgado et al., 2001; Juarranz
et al., 2005; Fernandez-Martin et al., 2006; Deng et al., 2010;
Jimeno et al., 2010; Ganea et al., 2015). VIP effects on
inflammatory-mediated autoimmune disorders are elicited, in
large measure, by induction of Tregs through tolerogenic DCs
(Chorny et al., 2005; Maldonado and von Andrian, 2010). In
PD, works from other and our laboratories have shown that
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VIP elicits significant dopaminergic neuroprotective responses
in PD models (Delgado and Ganea, 2003; Reynolds et al.,
2010; Olson et al., 2015). VIP is up-regulated in neuroimmune
cells after injury (Kim et al., 2000; Sandgren et al., 2003;
Nishimoto et al., 2011). VIP also affects inflammatory response
cascades, including mononuclear phagocytes (MP; macrophage
and microglia) and T cells by inhibiting production or release
of inflammatory cytokines such as tumor necrosis factor-alpha
(TNF-α) and interferon-gamma (IFN-γ) (Gonzalez-Rey and
Delgado, 2005, 2008; Delgado et al., 2008; Waschek, 2013;
Higyno et al., 2015). Furthermore, a critical aspect of the
underlying biology is that VIP has been shown to rebalance
the polarization of T cell responses from type-1 T helper cell
(Th1) and type-17 Th cell (Th17) toward a type-2 Th cell (Th2)
phenotype (Jimeno et al., 2012; Tan et al., 2015; VillanuevaRomero et al., 2018). Additionally, studies have demonstrated
that VIP elicits both natural and inducible subsets of Tregs
(Delgado et al., 2005; Fernandez-Martin et al., 2006; Szema et al.,
2011). The neuroprotective and immunomodulatory actions
of VIP, and the related pituitary adenylate cyclase activating
polypeptide (PACAP), support the idea for the development of
VIP- and PACAP-activated receptors as therapeutic targets for
neurodegenerative and neuroinflammatory diseases (Tan and
Waschek, 2011; Waschek, 2013; Olson et al., 2015, 2016).
We synthesized two novel agonists that discriminate VIPR1
and VIPR2 and exhibit increased systemic stability with
greater than 20-fold longer half-lives compared to native VIP
(Olson et al., 2015). Treatment of naïve animals with the
VIPR2 agonist, LBT-3627, increased Treg activity without
expanding Treg numbers. We previously compared the
neuroprotective capabilities of these selective peptides in an
acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
model of dopaminergic neurodegeneration. Pre-treatment with
the VIPR2 agonist, LBT-3627, provided robust and greater
dopaminergic neuronal protection compared to pre-treatment
with VIPR1 agonist or native VIP (Olson et al., 2015, 2016).
Additionally, adoptive transfer of Treg-mediated activity from
VIPR2 agonist- or VIP-treated animals decreased reactive
microglia numbers and pro-inflammatory cytokine production
by microglia (Reynolds et al., 2010; Olson et al., 2015). Moreover,
that co-transfer of VIP-induced Tregs with nitrated-α-Synspecific Th17 Teffs to MPTP intoxicated recipient mice provided
greater levels of neuroprotection than non-induced Tregs, and
that adoptive transfer of LBT-3627-induced Tregs afforded
greater neuroprotection than VIP-induced Tregs, highlight the
potential importance of VIPR2 agonists as a putative treatment
for neurodegenerative disorders.
Although LBT-3627 induced Treg-mediated neuroprotection
in MPTP intoxicated mice, whether VIPR2 agonist induction
of Tregs is conserved and protective in diverse models of
PD is not known. To these ends, the VIPR2 agonist, LBT3627 was tested for its abilities to augment Treg numbers and
function, and to elicit neuroprotective activities in two models
of nigrostriatal neurodegeneration. Stereotactically delivered
6-hydroxydopamine (6-OHDA) was used as a neurotoxic
alternative to MPTP as no known immune toxic effects have
been reported, while stereotactic overexpression of human α-Syn
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from adeno-association human α-Syn (AAV-α-Syn) constructs
was also used as the slower progression is considered a better
model to capture the pathobiology of PD (St Martin et al., 2007;
Theodore et al., 2008; Torres et al., 2011; Decressac et al., 2012).
Additionally, the 6-OHDA model was included as considerable
evidence showed VIP provided protective effects as demonstrated
by diminished oxidative stress and apoptosis, and improvements
in measures of dopaminergic neuron survival, spine densities
for medium spiny neurons, neurotransmitter levels, synaptic
plasticity, rotational behavior, and striatal astrocyte activity
(Tuncel et al., 2005, 2012; Korkmaz et al., 2010, 2012; Yelkenli
et al., 2016; Korkmaz and Tuncel, 2018). In these studies,
both immune function and neuroprotection by LBT-3627 were
evaluated in both models at multiple dose levels to determine
parallel model effects. The results indicated that LBT-3627
diminished the number of reactive microglia at all doses tested.
Moreover, we demonstrated that this VIPR2 agonist enhances
Treg function peripherally, which leads to attenuation of
microglial inflammatory responses and increased dopaminergic
neuroprotection at dose levels that can be translated for human
use. Lastly, due to the historical nature of VIP and the role
of VIP2R in vasodilation (Koga et al., 2014), initial pre-clinical
testing of LBT-3627 was performed for heart rate, pulse, and
systolic blood pressure. All readings recorded were within average
values. Taken together, we provide strong translational merit
toward moving forward a unique pharmaceutical agent for
PD neuroprotection.

control AAV2/1-IRES-eGFP-WPRE (AAV-GFP) (cat Standaert5712) were obtained from the University of Iowa Vector Core
(Iowa City, IA, United States) with kind permission from
Dr. David G. Standaert (Department of Neurology, University
of Alabama-Birmingham, Birmingham, AL, United States) (St
Martin et al., 2007; Theodore et al., 2008). For these studies,
3 × 109 genomic copies of AAV-vectors were delivered in
3 µl of PBS to the left hemisphere above the substantia
nigra at coordinates relative to the bregma, AP, −5.3 mm;
ML, −2.0 mm; and −7.5 mm according to the stereotaxic
atlas (Paxinos and Watson, 1986; Decressac et al., 2012). For
studies using 6-OHDA, rats received 10 µg of 6-OHDA in
5 µl PBS delivered to the right hemisphere above the medial
forebrain bundle at coordinates AP, −4.5 mm; ML, 1.5 mm; DV,
−7.3 mm, and relative to the bregma (Paxinos and Watson, 1986;
Torres et al., 2011).

Immunohistochemistry and Stereological
Analysis
Following administration of terminal pentobarbital anesthesia,
rats were transcardially perfused with DPBS followed by
4% paraformaldehyde in DPBS. The cohort that received
6-OHDA injections were euthanized on day 14, while the
cohort that received AAV-only injections were euthanized
on day 28. Brains were obtained and cryosectioned through
the ventral midbrain and striatum. Frozen midbrain sections
(30 µm) were collected in PBS as free-floating sections,
and every 8th section was immunostained for 48 h as
free-floating sections for tyrosine hydroxylase (TH) (antiTH, 1:2000, EMD Millipore, Burlington, MA, United States)
(Benner et al., 2008). Sections were washed and reacted with
biotinylated secondary antibody for 1 h and washed. To visualize
antibody-labeled tissues, sections were incubated in streptavidinHRP solution (ABC Elite Vector Kit, Vector Laboratories,
Burlingame, CA, United States) and color was developed
using a glucose/glucose oxidase/H2 O2 generation system and
diaminobenzidine (DAB) chromogen (Sigma-Aldrich). Sections
were mounted to microscope slides, counterstained for Nissl
substance, dried, coated with mounting medium (Cytoseal
60, Thermo Fisher Scientific), and covered with a coverslip.
To determine the microglia reactivity, midbrain sections were
immunostained as free-floating sections for ionized calcium
binding adaptor molecule 1 (Iba1) (anti-Iba1, 1:1000, Wako,
Richmond, VA, United States) and biotinylated secondary
antibody, and were visualized as previously described. The
slides were coded by an investigator not familiar with
treatment regimens and were assessed by blinded investigators.
Total numbers of reactive Iba1+ microglia/mm2 , TH+ Nissl+
(dopaminergic neurons), and TH− Nissl+ (non-dopaminergic)
neurons in the substantia nigra were determined by stereological
analyses using the Fractionator probe from StereoInvestigator
software (MBF Bioscience, Williston, VT, United States)
interfaced with an Eclipse 90i microscope (Nikon, Melville, NY,
United States). To sample through the substantia nigra using
every 8th section required 10 sections/rat for enumeration of
total nigral neurons and microglia density. The densities of

MATERIALS AND METHODS
Animals
Male 7-week old Sprague Dawley and Lewis rats were ordered
from SASCO and Charles River Laboratories, respectively.
Typical weights were 180–200 g at the time of surgery or
regulatory T cell (Treg) functional studies. All rodent procedures
were performed with approval of the UNMC Institutional
Animal Care and Use Committee and in accordance with NIH
Guide for the Care and Use of Laboratory Animals.

LBT-3627 Treatment and Stereotactic
Injections of 6-OHDA and AAV Vectors
Rats were treated initially with 5 daily s.c. doses of LBT3627 at 0.06, 0.2, 0.6, 2.0, or 6.0 mg/kg/100 µl dose. Animals
treated with an equal volume of PBS vehicle served as negative
controls. Immediately after delivery of AAV vectors or 6-OHDA,
rats began a regimen of LBT-3627 or vehicle for 5 days and
every other day thereafter. For stereotaxic delivery, rats were
anesthetized with 2% isoflurane in oxygen and placed in a
stereotaxic device (Leica Biosystems Inc., Buffalo Grove, IL,
United States). For each rat, the scalp was retracted to expose
the skull and a 1–2 mm hole was drilled in the skull. Injections
were accomplished using sterile Hamilton syringes (model 8100)
affixed with 26-gauge needles and delivered by with syringe
pump (LEGATO 210, cat 78-8212, KD Scientific, Holliston,
MA, United States). For α-Syn overexpression studies, AAV2/1α-SYN-IRES-eGFP-WPRE (AAV-α-Syn) (cat Standaert-5713) or
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TH+ expression for striatal termini were determined by digital
densitometry using image J software (National Institutes of
Health, Bethesda, MD, United States) (Benner et al., 2008). Briefly
for each rat, optical densities from 6 striatal sections stained
for expression of TH were obtained from bit map probes of
standardized areas, and background densities were determined
from non-striatal areas. Striatal TH densities were determined
for each section by subtracting the densities of background from
TH+ areas and the mean of the 6 sections served as the striatal
TH density/animal.

Fisher Scientific) and PE-anti-CD25 (2.5 µl, cat 554866, BD
Bioscience) and incubated on ice for 30 min. Cells were
washed with DPBS with 2% BSA and fixed. To probe for
intracellular transcription factors, cells were permeabilized
according to the manufacturer’s protocol (Permeabilization Kit,
cat 005523-00, eBioscience) and were reacted with APC-antiFoxp3 (5 µl, cat 77-5775-40, eBioscience) for 1 h. Samples
were analyzed using a BD LSRII flow cytometer and FACSDiva
Software (BD Biosciences) at the UNMC Center Flow Cytometry
Research Facility.

Treg Function Assessment

Statistics

CD4+ CD25+ and CD4+ CD25− T cells were isolated from rat
spleens using CD4+ T Cell isolation kit (cat 19642) and PE
selective kit (cat 18557) (StemCell, Vancouver, BC, Canada).
Briefly, isolated spleen cells were collected and placed in a petri
dish with 70 µm mesh cell strainer in 5 ml HBSS. A syringe
plunger was used to gently mash tissue to obtain single cells. Red
blood cells were removed with ACK lysis buffer (3 mL per spleen).
Spleen cells were stained to obtain CD4+ cells according to the
manufacturer’s protocol. CD4+ cells were stained with anti-CD25
PE (cat 55486, BD Biosciences, San Jose, CA, United States) for
20 min at a concentration of 0.75 µg/ml per 15 × 106 cells
and anti-PE-magnetic beads were used for positive selection of
CD4+ CD25+ T cells. These cells were greater than 90% Tregs as
determined by expression of forkhead box P3 (Foxp3) by flow
cytometric analysis (Figure 1B). The CD4+ CD25− T cell fraction
was collected in the flow through and served as conventional
responding T cells (Tresps) to be used in proliferation assays.
Tresps were labeled with carboxyfluorescein succinimidyl ester
(CFSE) (cat C34554, Thermo Fisher Scientific). Tregs were
serially diluted by twofold dilutions in a 96 well U-bottom
microtiter plate to contain 100, 50, 25, 12.5, and 6.25 × 103
Tregs in 100 µl of media. To each well was added 100 µl
of 50 × 103 CFSE-stained Tresps to yield Treg:Tresp ratios
of 2, 1, 0.5, 0.25, and 0.125:1, and Tresps in media served
as controls. To each well was added 25 × 103 rat T cell
activating CD3/CD28 beads (1 bead: 1 Tresp) and cultures
were incubated at 37◦ C in 5% CO2 for 72 h. The cells were
fixed with 1% formaldehyde in PBS and analyzed by flow
cytometric analysis. T cell activating CD3/CD28 beads were
prepared with Dynabeads M-450 epoxy (cat 14011, Thermo
Fisher Scientific) conjugated with anti-rat CD3 (cat 5012338,
Thermo Fisher Scientific) and anti-rat CD28 (cat 5014270,
Thermo Fisher Scientific) according to manufacturer’s protocol.
For conjugation, the CD3:CD28 ratio was 1:1 and bead to
antibody ratio was 1000 beads with 200 µg antibody (100 µg
CD3 and 100 µg CD28). Coupled beads were stored at 2–
8◦ C at a concentration of 4 × 107 beads/ml in PBS, pH 7.4
with 0.1% bovine serum albumin (BSA) and were utilized over
a 1 year period.

Data are presented as means ± SEM. Data were assessed for
normal distribution by probability plots against the theoretical
cumulative normal distribution function. Homoscedasticity
of data was assessed by Cochran C, Hartley, Bartlett test,
and Levene’s test. Normally distributed, homoscedastic data
were evaluated by parametric one-way ANOVA followed by
Newman-Keuls post hoc tests (Statistica, v13, TIBCO Software,
Inc., Palo Alto, CA, United States). Measurements of Treg
function were assessed by linear regression analyses as a
function of Treg:Tresp ratios. Differences in multiple linear Treg
functions were determined as significant differences in slope or
intercepts (Prism, v7, GraphPad Software, Inc., San Diego, CA,
United States).

Cardiovascular Safety Study in Dogs
The in vivo studies pertaining to this portion of the project
were performed at Charles River Laboratories, formerly WIL
Research Laboratories. All animals were housed individually
in clean stainless steel cages in an environmentally controlled
room. The cages were elevated above stainless steel flush
pans, which were cleaned daily. Animals were individually
housed as to prevent cross contamination as part of the
Latin-square cross over design. Dogs were maintained in
accordance with the Guide for the Care and Use of Laboratory
Animals (National Research Council, 2011). The facilities at WIL
Research were fully accredited by the Association for Assessment
and Accreditation of Laboratory Animal Care International
(AAALAC International). Environmental controls were set to
maintain a temperature of 71◦ F ± 5◦ F (22◦ C ± 3◦ C) and relative
humidity of 50% ± 20%. Temperature and relative humidity were
monitored continuously. Fluorescent lighting was set to provide
illumination for a 12-h light/12-h dark photoperiod. Reverse
osmosis-purified municipal water was available ad libitum.
Male Beagle dogs, 8–12 months of age and weighing
9.5 ± 038 kg, were previously implanted with radiotelemetry
transmitters and used in a Latin square cross-over design for
administration of LBT-3627 or vehicle (10 mM Tris + 267 mM
glucose, pH 8.5). Radiotelemetry implantation was performed by
Charles River Laboratories in naïve colonies of dogs following
standard operating procedures. The telemetrized dogs were
then maintained as a non-naïve colony for non-GLP CV
safety monitoring with an adequate washout period between
administrations of each test article. At the time of implantation,
dogs were surgically fitted with telemetry transmitters [TL11M3D70-PCTR, Data Sciences International (DSI), Minnesota,

Flow Cytometric Analysis
Blood was collected from the rat left atrium to determine
Treg number. Blood (50 µl) was stained with a mixture of
BV-421-anti-CD3 (2.5 µl, cat 563948, BD Bioscience), PerCPeFluor 710-anti-CD4 (2 µl, cat 46-0040-82, eBioscience, Thermo
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FIGURE 1 | Multiple doses of VIPR2 agonist augments Treg activity. Naïve Lewis rats were administered 5 daily s.c. injections of PBS vehicle (designated 0) or
LBT-3627 at doses of 0.06, 0.2, 0.6, 2.0, or 6.0 mg/kg (n = 5 rats/group). One day after last injection, cells from peripheral blood (A) and spleens (B) were assessed
for T cell and Treg frequencies. Percentages of cell populations included CD3+ T cells among lymphocytes (red circles), CD4+ T cells among CD3+ cells (blue
squares), CD25hi T cells among CD3+ CD4+ cells (green triangles), and CD25hi Foxp3+ among CD3+ CD4+ cells (purple inverted triangles). Mean percentages and
SEMs were determined from 5 rats/group and significant differences between dosages were assessed for each population by one-way ANOVA. P values for each T
cell population are denoted next to the concentration curve. (C) Spleen cells obtained from the above multiple-dosed animals (B) or from rats receiving a single s.c.
dose of LBT-3627 at 2.0 or 6.0 mg/kg (n = 5 rats/group) (D) were enriched for CD3+ CD4+ CD25hi Tregs and assessed for Treg function. Percent Treg-mediated
suppression was determined by flow cytometric analysis. Significant differences were determined from linear regression analysis with 5 rats/group and triplicate
assays for each rat. Regression analysis for all lines indicated that R2 > 0.96 with P values < 0.0054.

were on study with each of the 4 dogs receiving each dose
with at least a 3-day washout period in between any single
dose. The test compound, LBT-3627, was administered via s.c.
injection at 3 dose levels and a vehicle alone (0, 0.14, 0.6,
and 1.4 mg/kg). These dose levels were allometrically scaled
from the dose ranges that were observed to be effective to
prevent neurodegeneration in a mouse model of PD (Olson
et al., 2015). When scaled from dog, these doses would equate
to approximately 0.5, 2, and 5 mg/kg in rats, which is comparable

United States] into the abdominal cavity under anesthesia.
The transmitters have a fluid-filled catheter (coated with an
antithrombotic film to inhibit thrombus formation) with the
tip filled with a patented gel for blood pressure collection,
and 2 ECG leads surgically implanted emulating a Lead II
configuration. All dogs were allowed to recover for at least
2 weeks from the implantation of the telemetry device before
administration of the test articles. LBT-3627 was provided to
WIL Research by Longevity Biotech, Inc. A total of 4 dogs
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Dopaminergic Neurodegeneration and
Reactive Microgliosis Are Induced by
Human Wild Type α-Syn Overexpression

to the three doses used in the current neurodegenerative models
(0.6, 2, and 6 mg/kg).
Following a single injection of the test compound or
vehicle to the dog, a host of parameters were tracked by
radiotelemetry. Clinical observations included detailed daily
physical examinations (before and after dosing) and continual
observation for the first 4 h after dosing. Dogs were also
weighed before, after, and throughout the study. Baseline
arterial blood pressure (systolic, diastolic, and mean), pulse
pressure, heart rate, electrocardiographic (ECG) waveforms,
and body temperature were collected continuously for 1 h
prior to administration of vehicle or test compound. Following
administration of vehicle or test compound, the same parameters
were collected continuously for at least 24 h. Cardiovascular
parameters and body temperature data were averaged for 4 dogs
per group to appropriate time intervals for statistical analysis.
Two way ANOVA was used to determine statistically significant
differences between groups over time for each of the parameters
that were tracked.

We utilized the overexpression of human α-Syn in rat ventral
midbrain as a model of dopaminergic neurodegeneration to
assess putative neuroprotective modalities. Initially, to delineate
the kinetics of neurodegeneration and inflammation in that
model, Sprague-Dawley rats were stereotactically injected in
the left hemisphere with AAV-α-Syn, AAV-GFP, or were shamtreated by insertion of the needle into the dura without infusion
(SHAM). At 21, 28, and 35 days post-injection, animals were
sacrificed, brains collected, processed, sectioned through the
ventral midbrain and striatum, and stained for expression
of TH for dopaminergic neurons and termini. TH staining
was similar in sections isolated from rats treated with either
sham (Figure 2A) or AAV-GFP (Figure 2B) in ipsilateral
and contralateral hemispheres of the ventral midbrain and the
striatum regardless of time after viral treatment indicating that
viral delivery itself resulted in little if any neurodegenerative
effect. In contrast, TH staining from animals treated with AAVα-Syn showed reductions of TH staining within the substantia
nigra and striatum of the ipsilateral hemisphere compared to
the non-injected contralateral hemisphere (Figure 2C). These
reductions are particularly evident 28 and 35 days after infection.
To validate those observations, we counted TH+ and TH−
neuronal numbers in both the ipsilateral and contralateral
hemispheres by stereological analysis and compared ratios of
ipsilateral and contralateral neuronal counts. Significant loss
of TH+ Nissl+ neurons were not detected after treatment
with AAV-GFP vector as ipsilateral/contralateral ratios at any
time were greater than 0.91 and P > 0.3225 (Figure 2D).
However, treatment with AAV-α-Syn resulted in 24, 36, and
55% loss of TH+ Nissl+ neurons correlating to diminution of
ipsilateral/contralateral ratios of 0.77, 0.53, and 0.41 on days
21, 28, and 35, respectively. No significant effects of treatment
and/or day were detectable for non-dopaminergic (TH− Nissl+ )
neurons within the substantia nigra (P > 0.4603). While densities
of striatal TH+ termini were slightly diminished 21 days after
treatment with AAV-α-Syn, significant diminution was realized
only after 28 and 35 days compared to treatment with AAVGFP (Figure 2E).
To assess the effects of α-Syn overexpression on
neuroinflammation, sections of ventral midbrain were stained
for Iba1 expression. Iba1+ microglia from sham (Figure 3A)
and AAV-GFP (Figure 3B) treated rats showed mostly ramified
morphologies with densities that were unaffected regardless
of hemisphere, treatment regimen, or time after treatment.
In contrast, by day 21 and through day 35 after AAV-α-Syn
treatment, staining of amoeboid Iba1+ microglia were increased
in the ipsilateral hemisphere compared to the contralateral
hemisphere (Figure 3C). Stereological analysis confirmed these
observations showing that ipsilateral/contralateral ratios of
microglial densities (1.0 – 1.3) for AAV-GFP treated animals
were not significantly different; however, AAV-α-Syn treatment
increased those ratios to 4.2-fold by days 21 and 28 post-injection
(Figure 3D). By day 35, the ratio diminished to twofold, which

RESULTS
Multiple Doses of VIPR2 Agonist
Increase Treg Activity Without Expanding
CD4+ T Cells or Tregs
To assess the effects of VIPR2 agonist on Treg numbers and
function, we treated rats with 5 daily s.c. doses of LBT3627 at 0.06, 0.2, 0.6, 2.0, or 6.0 mg/kg/dose or with PBS
vehicle (0 mg/kg). The day after the last injection, T cell
and Treg frequencies from peripheral blood and spleens were
assessed. Compared to vehicle-treated controls, no significant
differences were detected in percentages of (a) CD3+ T cells
among lymphocytes, (b) CD4+ T cells among CD3+ T cells,
CD25hi T cells among CD3+ CD4+ T cells, or CD25hi Foxp3+
Tregs among CD3+ CD4+ T cells in either peripheral blood
(P value ranges = 0.5807 – 0.9583) (Figure 1A) or spleen
(P value ranges = 0.3477 – 0.9999) (Figure 1B). Spleen cells
from individual animals were enriched for CD3+ CD4+ CD25hi
Tregs and assessed for suppressive activity toward Tresp.
Flow cytometric analysis indicated those CD4+ CD25+ T cells
exhibited a Treg phenotype with greater than 90% expressing
Foxp3 (Figure 1B). Compared to animals treated with vehicle,
Treg activity was significantly increased in animals treated with
LBT-3627 at 0.6. 2.0, and 6.0 mg/kg once daily for 5 days, but
no effect was detected in rats treated with lower concentrations
at 0.06 and 0.2 mg/kg (Figure 1C). We also assessed whether a
single dose of VIPR2 agonist was sufficient to upregulate Treg
activity. We found that one dose of LBT-3627 at levels required
to upregulate Treg activity with multiple doses did not alter
Treg activity compared to control (Pslope and Pintercept > 0.8702)
(Figure 1D). These data together demonstrated that LBT-3627
elevates Treg function without increasing frequencies and that
multiple doses of LBT-3627 are necessary to increase Treg
activity. Those effective dosing paradigms were chosen for
evaluation in the two neurodegenerative models.
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FIGURE 2 | Dopaminergic neurodegeneration by overexpression of human α-Syn. Sprague-Dawley rats were stereotactically sham injected without infusion
(n = 3/day) (A) or injected with either AAV-GFP vector (n = 5/day) (B) or AAV-α-Syn vector (n = 4–5/day) (C). Brains were removed on days 21, 28, and 35 post
injection. Sections of midbrain and striatum were stained to visualize tyrosine hydroxylase (TH) expression to reveal dopaminergic neurons in the substantia nigra and
efferent termini in the striata. (D) Ipsilateral/contralateral ratios of TH+ Nissl+ (red bars) and TH+ Nissl− (blue bars) neuron numbers as determined from stereological
analysis. (E) Ipsilateral/contralateral ratios of TH+ striatal densities as determined from digital image analysis. Means and SEM were determined from 4 to 5
rats/group. Significant differences were assessed by one-way ANOVA and Newman-Keuls post hoc tests. P-values are denoted above connecting comparisons.
Scale bars, 1000 µm.

VIPR2 Agonist Protects From
Dopaminergic Neurodegeneration and
Attenuates Neuroinflammation Induced
by α-Syn Overexpression

was significantly lower compared to those on day 21 and 28
(P < 0.0003), but not significantly different than AAV-GFP
treated animals. These data suggested that by day 35, reactive
microglia responses were beginning to be resolved, even in the
context of progressive dopaminergic neuronal loss. Thus, we
selected day 28 after AAV-α-Syn injection as an optimal time
to assess the neuroprotective and anti-inflammatory capacities
of VIPR2 agonist.
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To assess the effects of a VIPR2 agonist on neurodegeneration
by α-Syn overexpression, we stereotactically injected rats with
AAV-α-Syn and administered LBT-3627 in 5 sequential daily s.c.
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FIGURE 3 | Human α-Syn overexpression increases reactive microglia. Sprague-Dawley rats (Figure 2) were stereotactically injected without infusion (SHAM)
(n = 3/day) (A) or injected with either AAV-GFP vector (n = 5/day) (B) or AAV-α-Syn vector (n = 4–5/day) (C). Brains were removed on days 21, 28, and 35 post
injection. Sections of midbrain were stained to visualize Iba1 expression to reveal reactive microglia in the substantia nigra. (D) Numbers of Iba1+ amoeboid
microglia were estimated by stereological analysis. Means and SEM were determined from 4 to 5 rats/group. Significant differences were assessed by one-way
ANOVA and Newman-Keuls post hoc tests. P-values are denoted above connecting comparisons. Scale bar, 40 µm.

doses, followed by one dose every other day thereafter. Drug
concentrations of 0, 0.6, 2.0, or 6.0 mg/kg/dose were delivered
to each group. Control groups were treated with AAV-GFP or
LBT-3627 vehicles. Assessment of brain sections from 28 days
after AAV injections revealed that AAV-α-Syn led to reduced
TH expression in the substantia nigra and striata compared
to sham and AAV-GFP controls (Figure 4A). In contrast,
intensities of TH expression within the ipsilateral hemispheres
were increased in ipsilateral sections of the substantia nigra
and striatum from AAV-α-Syn rats treated with LBT-3627
compared to those sections from vehicle-treated AAV-α-Syn
rats. Stereological analysis validated findings within the nigra
which demonstrated differences between the ipsilateral and
contralateral hemispheres taken as ratios of TH+ neurons
(Figure 4B). TH+ neuron ratios were significantly diminished in
AAV-α-Syn treated animals compared to sham- and GFP-treated
rats. While treatment with LBT-3627 after AAV-α-Syn injection
increased TH+ neuron ratios, only 2.0 mg/kg significantly
increased the ipsilateral/contralateral ratio by 43% compared
to rats treated with AAV-α-Syn and vehicle. The increase
ratio was due to increased numbers of dopaminergic neurons
in the ipsilateral hemisphere compared to that of the AAVα-Syn controls. Additionally, 2.0 mg/kg of LBT-3627 significantly
spared the density of striatal TH+ termini by 24% compared to
AAV-α-Syn controls (Figure 4C).
During the same study, we also assessed the effects of VIPR2
agonist on microglia-mediated neuroinflammatory responses.
Sections of ventral midbrain from the above studies were probed
for Iba1 expression and the densities of Iba1+ reactive microglia
were measured. Sections showed that microglial morphologies
and Iba1 intensities in ipsilateral and contralateral hemispheres
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were virtually identical 28 days after sham or AAV-GFP treatment
(Figure 5). In contrast, α-Syn overexpression increased the
intensity of staining for Iba1+ amoeboid microglia within
the ipsilateral ventral midbrain compared to the contralateral
hemisphere. LBT-3627 treatment diminished the intensity of
Iba-1 staining in tissues from rats overexpressing α-Syn. To
validate those observations, we enumerated reactive microglial
by stereological analyses. AAV-α-Syn overexpression increased
the numbers of ipsilateral Iba1+ reactive microglia by 2.5-fold
compared to the contralateral hemisphere. Treatment with LBT3627 at doses of 0.6, 2.0, and 6.0 mg/kg reduced reactive microglia
by 26, 27, and 36%, respectively. Interestingly, doses of 6.0 mg/kg
returned microglia numbers to levels not significantly different
from either sham or AAV-GFP controls, resulting in nearly
complete ablation of the microglia response.

VIPR2 Agonist Rescues Treg Activity
Diminished by α-Syn Overexpression
As Treg function has been shown to be deficient in both PD
patients and in mice immunized with α-Syn, and since LBT3627 augments Treg activity with subsequent neuroprotection
(Reynolds et al., 2010; Saunders et al., 2012; Olson et al., 2015),
we assessed the effects of VIPR2 activation on Treg numbers and
function in the context of α-Syn overexpression. As described
above, rats were stereotactically injected with AAV-α-Syn and
treated with varying doses of LBT-36327. After 28 days, splenic
cells were enriched for Tresp and Treg populations and tested
for proliferative or suppressive functions, respectively. Tresps
were stained with CFSE, stimulated with CD3/CD28 beads in the
absence of Tregs, and assessed by flow cytometric analysis for
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FIGURE 4 | VIPR2 agonist protects dopaminergic neurons from α-Syn-mediated neurodegeneration. Sprague-Dawley rats were stereotactically injected, but not
infused (SHAM) (n = 5) or infused with AAV-GFP (n = 6) or AAV-α-Syn vector (n = 6–7/group). AAV-α-Syn-treated rats began a regimen of PBS (0) (n = 7) or LBT-3627
at doses of 0.6, 2.0, or 6.0 mg/kg (n = 6/group) administered as daily s.c. injections for 5 days and every other day thereafter. On day 28 after infection, brains were
obtained and sections of midbrain and striatum were stained for expression of TH (A). (B) Numbers of TH+ neurons were assessed in the substantia nigra by
stereological analysis and ipsilateral/contralateral ratios calculated. (C) Ipsilateral/contralateral ratios of TH+ densities were determined from digital image analysis of
striatal TH expression. Means and SEM were determined from 5 to 7 rats/group. Significant differences were assessed by one-way ANOVA and Newman-Keuls
post hoc tests. P ≤ 0.05 compared to treatment as a sham controls, b AAV-GFP, or animals treated with AAV-α-Syn and c 0 (vehicle), d 0.6, or e 2.0 mg/kg LBT-3627.
Scale bars, 1000 µm.

proliferative capacity after 3 days of incubation. No significant
differences in the percentages of proliferating Tresps were
discernable between treatment groups (P = 0.2028) (Figure 6A).
In contrast, Treg function from AAV-α-Syn-treated rats (red
line) was significantly diminished compared to Treg function
from AAV-GFP controls (blue line) (P = 0.0115) (Figure 6B).
Treatment with 0.6 mg/kg of LBT-3627 (green line) increased
Treg function compared to that from AAV-α-Syn alone treated
rats (P = 0.0065), but was still lower than that from AAVGFP controls (blue line) (P = 0.0168). Only doses of 2.0
(purple) and 6.0 (orange) mg/kg of LBT-3627 were sufficient to
increase Treg activity above that of GFP controls (P < 0.007).
While no significant differences in Treg function were detected
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between 2.0 and 6.0 mg/kg doses, 2.0 mg/kg doses of LBT-3627
tended to show better efficacy affecting Treg function and TH+
neuron survival.

Higher Doses of VIPR2 Agonist Are
Required to Protect Dopaminergic
Neurons in the 6-OHDA Model
We sought to validate the neuroprotective capacity of VIPR2
agonist in a second model of dopaminergic neurodegeneration.
For these studies, 6-OHDA was delivered to the medial forebrain
bundle by stereotactic injection into the left hemisphere while the
contralateral hemisphere served as a control. Following a similar

9

September 2019 | Volume 13 | Article 421

Mosley et al.

VIPR2 Agonist Induced Treg Neuroprotection

FIGURE 5 | VIPR2 agonist diminishes microglial response to α-Syn overexpression. Sprague-Dawley rats were treated as sham control (n = 5) or stereotactically
injected with AAV-GFP (N = 6) or AAV-α-Syn vector (n = 6–7/group). AAV-α-Syn-treated rats started the same regimen as in Figure 4 of vehicle (0) (n = 7) or
LBT-3627 administered at 0.6, 2.0, or 6.0 mg/kg (n = 6/group). On day 28 after infection, brains were obtained and sections of midbrain were stained for expression
of Iba1 by microglia. Numbers of Iba1+ amoeboid microglia were determined by stereological analysis. Means and SEM were determined from 5 to 7 rats/group.
Significant differences were assessed by one-way ANOVA and Newman-Keuls post hoc tests. P ≤ 0.05 compared to treatments as a sham controls, b AAV-GFP, or
AAV-α-Syn and c PBS. Scale bar, 40 µm.

FIGURE 6 | VIPR2 augments Treg activity in rats overexpressing human α-Syn. Sprague-Dawley rats were treated by stereotaxic injection with AAV-GFP (n = 3) or
AAV-α-Syn vector. Rats treated with AAV-α-Syn-began a regimen of LBT-3627 administrated at 0.6, 2.0, or 6.0 mg/kg or vehicle (0 mg/kg) (n = 3/group) by daily
administration for 5 days and every other day thereafter. On day 28 after infection, spleen cells were enriched for conventional CD4+ T cells and assessed for
percentage of proliferating T cells (A), or enriched for Tregs and assessed for percentage inhibition of proliferating T cells (B). Note, treatment regimens for (A,B) are
color-matched. (A) Means and SEM were determined for 3 rats/group. No significant differences were detected by one way ANOVA, P = 0.2028. (B) Significant
differences of Treg activities between treatment groups were determined from linear regression analysis of 3 rats/group. Regression analysis for all treatments
indicated that each regression exhibited R2 > 0.83 with P values < 0.032.

showed substantive loss of TH expression within the substantia
nigra of the ipsilateral hemisphere compared to the contralateral
side (Figure 7A). Meanwhile, examination of sections from
animals treated with LBT-3627 suggested that ipsilateral
expression of TH in the substantia nigra was increased in a
dose-dependent fashion compared to 6-OHDA controls. TH+

dosing paradigm as described above, immediately after 6-OHDA
delivery, LBT-3627 at doses of 0.6, 2.0, or 6.0 mg/kg was initiated
with 5 daily s.c. injections followed every other day thereafter
until day 21 post-injection. A control group included rats that
received 6-OHDA and were treated with vehicle alone. Sections
of midbrain and striatum immunostained for TH expression
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FIGURE 7 | VIPR2 agonist protects dopaminergic neurons and diminishes microglial response after 6-OHDA. Lewis rats were administered 10 µg of 6-OHDA in 5 µl
of PBS by stereotaxic injection or were injected without infusion (SHAM controls) (n = 6). Immediately after injection, rats began a regimen of either vehicle
(0.0 mg/kg) (n = 5) or 0.6 (n = 6), 2.0 (n = 6), or 6.0 (n = 5) mg/kg of LBT-3627 administered as daily injections for 5 days and every other day thereafter. After
14 days, brains were obtained, processed and stained for expression of TH in the substantia nigra (A) and striatum (B), and for Iba1 in the substantia nigra (C).
(D) TH+ Nissl+ (red bars) and TH− Nissl+ (blue bars) neurons within the substantia nigra were counted by stereological analysis and the ipsilateral/contralateral ratios
of those numbers were determined. No significant differences in TH− Nissl+ neurons were discernible between treatment groups, P = 0.7671. (E) Densities of TH+
termini were determined by digital image analysis and ipsilateral/contralateral ratios of those densities calculated. (F) Densities of amoeboid Iba1+ microglia were
assessed by stereological analysis and ipsilateral/contralateral ratios of those densities were determined. (D–F) Means and SEM were calculated for 5–6 rats/group.
Significant differences were assessed by one-way ANOVA followed by Newman-Keuls post hoc tests. P ≤ 0.05 compared to animals treated as a sham controls or
with b 6-OHDA + vehicle (0 mg/kg). Scale bars, (A,B) 1000 µm and (C) 40 µm.

the ventral midbrain, revealed that 6-OHDA treatment
induced an intense activated microglial response (Figure 7C).
Treatment with LBT-3627 at all doses substantially decreased
neuroinflammatory responses as exhibited by diminished

stained termini in the striatum indicated that 6-OHDA resulted
in a profound loss of TH expression in the ipsilateral hemisphere
compared to contralateral hemisphere (Figure 7B). Additionally,
sections stained for Iba1+ reactive amoeboid microglia in
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Iba-1 expression intensity. Stereological analysis of TH+ Nissl+
neurons within the ipsilateral substantia nigra revealed a 73%
loss of dopaminergic neurons by 6-OHDA compared to sham
control (Figure 7D). Treatment with 6.0 mg/kg of LBT-3627
spared 53% of the dopaminergic neurons, whereas doses of
0.6 and 2.0 mg/kg showed no significant effect compared to
6-OHDA control. No effect on TH− Nissl+ non-dopaminergic
neurons was detected (P = 0.7671). Digital image analysis of
TH+ striatal termini showed a 41% loss of dopaminergic termini
compared to sham controls, and regardless of LBT-3627 dose,
losses of striatal termini were not significantly different from
6-OHDA controls (P > 0.1226) (Figure 7E). Meanwhile, to
measure the inflammatory response of 6-OHDA, the density
of Iba1+ reactive amoeboid microglia were determined by
stereological analysis. 6-OHDA induced a 22.6-fold increase in
the density of reactive microglia in the ipsilateral hemisphere
compared to that of the sham control (Figure 7F). Treatment
with LBT-3627 decreased reactive microglia densities in the
SN by 57–61%, regardless of dose. Taken together these data
indicate that LBT-3627 is neuroprotective at the 6 mg/kg
dose in 6-OHDA-induced dopaminergic neurodegeneration,
while attenuation of microglial-mediated neuroinflammatory
responses was possible at all dose levels evaluated.

regulation of lymphocytic Th1/Th2/Th17 differentiation (Voice
et al., 2004; Jimeno et al., 2012; Tan et al., 2015; VillanuevaRomero et al., 2018), and alterations of immunoglobulin
production by B lymphocytes (Samarasinghe et al., 2011; Xu et al.,
2014). Our prior works also show that VIP and selective VIPR1
and VIPR2 receptor analogs affect Treg activity (Reynolds et al.,
2010; Olson et al., 2015, 2016). In the setting of neurodegenerative
diseases, VIP and VIP-based analogs downregulate microglia
pro-inflammatory activities and spare dopaminergic neuronal
damage in the nigra and striatum. These activities appear to
be Treg-mediated as adoptive transfer from VIP-treated donors
with α-Syn-specific Th17 effectors resulted in dopaminergic
neuroprotection (Reynolds et al., 2010). Parallel experiments
wherein Tregs were transferred from naïve donors were not
as protective. In each of these cases, Treg-mediated activities
induced by VIPR2 agonist performed better than those induced
by VIPR1 agonist or native VIP (Olson et al., 2015). All together,
these data show the importance of the VIPR2 receptor, not only as
an immune modulator, but also as a potentiator of Treg-mediated
neuroprotection (Dejda et al., 2005; Rangon et al., 2005; Delgado
et al., 2008; Reynolds et al., 2010; Shioda and Gozes, 2011; Olson
et al., 2015, 2016; Deng and Jin, 2017).
In parallel, VIP is associated with adverse effects in the
gastrointestinal and the CNS (Bloom et al., 1973; Said and
Faloona, 1975; Bloom, 1978; Kane et al., 1983; Guelrud et al.,
1992; Masel et al., 2000; Cernuda-Morollon et al., 2015; Riesco
et al., 2017). VIP’s effects are due in large part by engaged
signaling pathways associated with binding of specific receptors
preferentially expressed by specific cell types. For instance,
VIPR1 is preferentially expressed by gastrointestinal tissues,
while VIPR2 is relegated largely to smooth muscle, lung, and
myocardial organs (Schulz et al., 2015; Jayawardena et al., 2017).
In the immune system, early reports suggested that modulatory
effects were associated with the constitutively expressed VIPR1,
however, recent data suggest that induced VIPR2 may play
a larger role than previously suggested, especially for Treg
induction or potentiation of suppressive function (Goetzl et al.,
2001; Martinez et al., 2002; Samarasinghe et al., 2011; Olson et al.,
2015, 2016). We recently synthesized specific agonists specific
for VIPR1 or VIPR2 that do not interact with ADCYAP1R1
(PAC1), and display increased metabolic stability compared to
VIP (Olson et al., 2015). We demonstrated that pretreatment
with the VIPR2-specific agonist, LBT-3627, but not a VIPR1
agonist (LBT-3393), potentiated Treg neuroprotective activity
in a dose-dependent manner in MPTP mice. These results
supported Treg induction experiments in VIPR knockout
animals which concluded that VIPR2, rather than VIPR1
plays a greater role in VIP-mediated augmentation of Tregs
(Yadav et al., 2011; Tan et al., 2015). Moreover, adoptive
transfer studies demonstrated that cells from LBT-3627-treated
animals provide significantly greater protection for dopaminergic
neurons in MPTP mice than that provided by VIPR1 agonist
(Olson et al., 2015, 2016). However, whether VIPR2 agonist
functions in different species and affords neuroprotection in
more progressive models of dopaminergic neurodegeneration
awaits further investigation.
In establishing the neuroprotective profile of VIPR2,
adoptive transfer techniques were necessary to overcome

LBT-3627 Tests on Cardiovascular
Metrics
Despite
promising
immunomodulatory
and
related
neuroprotective effects of VIPR2 activation observed in
both rat models investigated in this report, a major gap between
preclinical and human efficacy existed. To advance this VIPR2
strategy toward clinical evaluations warranted safety evaluations
of LBT-3627. Thus, we administered LBT-3627 by subcutaneous
(s.c.) injection to dogs at doses of 0.14, 0.6, and 1.4 mg/kg, which
were allometrically scaled to mirror dose concentrations required
for Treg induction. After the single injection of LBT-3627, dogs
were monitored telemetrically for heart rate, pulse pressure,
systolic blood pressure, diastolic blood pressure, and corrected
Van de Water’s QT (QTcV) interval (Figure 8). At the lowest
dose level, none of the monitored parameters were changed
over placebo during a 24-h observation period. At the two
higher doses, transient, but limited, increases in heart rate,
decreases in pulse pressure, and reductions in systolic pressure
were observed. All changes were within the historical range of
baselines as indicated by the dotted horizontal boundaries in all
plots (Figures 8A–E).

DISCUSSION
The study provides further evidence that modulation of adaptive
immunity through the production of Tregs leads to significant
neuroprotection in PD animal models. As a peptide hormone
and neurotransmitter, VIP’s pleotropic effects modulate innate
and adaptive immunity (Delgado et al., 2004; Pozo and Delgado,
2004; Reynolds et al., 2010; Ganea et al., 2015; Olson et al., 2015)
that include the inhibition of macrophage and microglial release
of inflammatory mediators (Gonzalez-Rey and Delgado, 2005,
2008; Delgado et al., 2008; Waschek, 2013; Higyno et al., 2015),
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FIGURE 8 | VIPR2 agonist does not induce any overtly concerning effects on CV parameters. LBT-3627 was administered subcutaneously to beagle dogs at three
dose levels (1× minimum effective dose (MED) = 0.14 mg/kg, 3× MED = 0.6 mg/kg, and 10× MED = 1.4 mg/kg), plus a vehicle only control (placebo), that
allometrically scale to approximately match the three dose levels used in the neuroprotection portion of this study (0.6, 2.0, and 6.0 mg/kg) (n = 4/group). CV
parameters were tracked for 24 h after the single s.c. injection. Additionally, horizontal dotted lines indicate the historic baseline averages, plus and minus one
standard deviation, for the dogs within the testing colony. For the lowest dose level (1× MED), none of the CV parameters were significantly modulated compared to
placebo (A–E). Heart rate was significantly increased for both 3× and 10× MED for the first 3–4 h after administration and returned to placebo levels after 4 h (A).
Pulse pressure mirrors this response and is increased for the 3× and 10× MED groups for the first 4 h (B). This increase in pulse pressure can be attributed
to the increase in systolic pressure (C), since the diastolic pressure was not modulated for any dose level compared to placebo (D). QTcV interval was unaltered for any
(Continued)
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FIGURE 8 | Continued
dose level compared to placebo as well (E). Means and standard deviations were calculated for 4 dogs/group and significant differences were assessed by two-way
ANOVA with Dunnett’s post hoc tests. Compared to placebo treated animals, designated P values were ∗ ≤0.05, ∗∗ ≤0.01, ∗∗∗ ≤0.001, or ∗∗∗∗ ≤0.0001.

immunotoxicities intrinsic to the MPTP model. Herein, we
used two different animal models that are not inherently
immunotoxic and, therefore, preclude the need for adoptive
transfer to evade toxicities and elicit neuroprotection. The
α-Syn overexpression model results from this study are
particularly interesting as they establish a clear link between
human PD pathology (accumulation of α-Syn in the brain) and
immune system dysregulation of innate and Treg functions
(Figures 3, 6). Of particular interest is that each dose level
of LBT-3627 tested reduced microglial activation regardless
of dose. Most interestingly, the middle dose of LBT-3627
(2.0 mg/kg), which trended to provide the highest suppressive
activity, paralleled neuroprotection. Similar observations were
recorded in the 6-OHDA rat model, wherein LBT-3627 reduced
microglial activation across all three dose levels, but only the
highest dose (6.0 mg/kg) was sufficient to afford significant
neuronal survival. While the exact biological cascade fully
describing how VIPR2 activation in the periphery leads to
central neuroprotection remains incomplete, it is clear that
peripheral T cell function plays a critical role. Several groups,
ours included, are investigating specific genomic pathways
outlining the crosstalk between CNS and immune compartments
(Reynolds et al., 2010; Ransohoff and Brown, 2012; Kosloski
et al., 2013; Anderson et al., 2014; Olson et al., 2015; Chan et al.,
2016; Gendelman et al., 2017; Schutt et al., 2018; Limanaqi et al.,
2019). Other groups have reported that the parenchyma and/or
choroid plexus contribute to the crosstalk, which becomes more
pronounced in diseased states, while others have sidestepped the
issue and allude to passive diffusion pathways (Xu et al., 2010;
Nunan et al., 2014; Balusu et al., 2016; Jayawardena et al., 2017;
Marques et al., 2017; Arcuri et al., 2019).
However, should subsequent work determine that VIPR2
agonist is indeed directly responsible for both peripheral
and central observations noted herein, without additional
messengers, the neurotrophic aspects of the VIPR2 receptor
would come into play. Specifically, VIP interneurons play several
key roles in cognition. Recent work has revealed that VIP
interneurons are able to affect the function of downstream
pyramidal neurons. In optogenetic animal models, activation
of these VIP interneurons improved memory retention over
negative controls (Kamigaki and Dan, 2017). Furthermore,
activation or disinhibition of these neurons, releases a selfimposed suppression on interneuron neurotransmitter signaling
(Lee et al., 2013; Pi et al., 2013; Fu et al., 2014; Stryker,
2014; Zhang et al., 2014). Perhaps an underlying cause for this
biological cascade affects circadian rhythm aspects relevant to
VIP biology (Ono et al., 2016).
Aside from the biology described above, VIP is also
responsible for attenuating microgliosis (Kim et al., 2000;
Dejda et al., 2005; Waschek, 2013). This orthogonal, yet direct,
mechanism of action is also beneficial in the context of a
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neurodegenerative disorder. If the complex biological pathways
and peripheral to central crosstalk thesis is ignored as “too
complex,” one must conclude that the VIPR2 agonist is a
lone actor with central actions being all neuroprotective in the
diseased state and ultimately resulting in improved memory
recall. While much work remains to be done to understand
the peripheral to central transduction pathway along with a
multitude of downstream molecular actors involved, the results
herein clearly indicate that something is transferring from
the peripheral to central compartments resulting in robust
neuroprotection with attenuation of microgliosis. Therefore,
based on our collective work, we proposed that VIPR2 activation,
though minimally on Tregs, but potentially on other cell types,
initiates a cascade of biological events that include (1) improved
peripheral Treg function, (2) reduced reactive microglia inside
the central compartment, (3) shifted balance of multiple proand anti-inflammatory cytokines, and (4) robust, dose responsemediated neuroprotection of TH+ dopaminergic neurons.
Interestingly, an optimal range in the VIPR2 agonist dose
appears to be necessary for Treg functional improvement in
terms of neuroprotection. Specifically, in our earlier work,
high concentrations of VIPR2 agonists result in a decrease in
cAMP production via cell-based assays (Olson et al., 2015).
This has been attributed to GPCR activation-induced receptor
internalization (Valdehita et al., 2010). The rescue of Treg
function in the α-Syn model was evident at the same dose
(2 mg/kg) that induced the greatest neuroprotection. On the
other hand, neuroprotection in the 6-OHDA model was attained
only at the highest dose level. The case may be made that an
appropriate balance must be achieved under different disease
processes and conditions, and that a standard dose level may
not be the best for each different set of circumstances. Another
explanation to the non-traditional dose-response outcomes for
neuroprotection in the α-Syn model may lie within the complex
GPCR biological cascades that act through cAMP, β-arrestin1 or
β-arrestin2 as second messengers. Furthermore, these underlying
circuits may be wired differently for different cell types, possibly
explaining the nuanced results reported herein. Multi-omic
approaches would shed additional light on the specific wiring of
this therapeutic pathway.
Regardless of the disease model, all dosing regimens of
LBT-3627 reduced numbers of inflammatory microglia. For
the overexpression of α-Syn model, treatment with LBT-3627
caused a dose-dependent reduction in microglial activation with
6 mg/kg yielding microglia levels indiscernible from sham or
GFP controls, albeit not yielding statistically different levels from
the other two lower doses. Similarly, LBT-3627 in 6-OHDA
treated animals reduced microglia equally, regardless of dose,
but did not attain levels of sham controls. This dichotomy
may be due, in part, to different intensities of microglial
responses in each model. Numbers of inflammatory microglia in
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6-OHDA-treated animals increased 24-fold compared to sham
controls, whereas overexpression of α-Syn increased microglial
numbers by only 2.6-fold compared to sham controls. Thus,
microglial responses in 6-OHDA treated rats intensities were
10-fold greater than those in α-Syn overexpression animals.
The intensity of the microglial response may also affect the
adaptive immune responses and exacerbate neuroinflammation
and neurodegeneration as previously reported and reviewed
(Benner et al., 2008; Gendelman and Mosley, 2015; Mosley
and Gendelman, 2017). Indeed, 6-OHDA treated mice also
have been reported to exhibit an extensive microglial response
associated with IgG deposition, increased infiltration of T
and B cells, and exacerbated dopaminergic neurodegeneration
(Theodore and Maragos, 2015). Moreover, α-Syn overexpression
induced an average of 50% dopaminergic neuronal loss in
the substantia nigra, whereas 6-OHDA induced a 75% loss.
Together, these data suggest that 6-OHDA induces greater
severity of neuroinflammation and neurodegeneration than
α-Syn overexpression.
It is well-known that peripheral VIPR2 activation can be
directly attributed to central neuroprotection along with a
reduction in microgliosis. Using doses of 2 mg/kg LBT-3627
led to protection of dopaminergic neurons in the SNpc and
their terminal processes in the striatum reflecting our own
prior works in MPTP intoxicated animals (Olson et al., 2015).
Notably, doses of 2 mg/kg nearly restored striatal density to levels
of AAV-GFP controls (Figure 4C). Nonetheless, in 6-OHDAtreated rats, doses of 2 mg/kg LBT-3627 were insufficient to
elicit neuroprotection along the nigrostriatal axis and required at
least 6 mg/kg to protect nigral neurons. Alternatively, differences
in the exhibited effective doses for neuroprotection between
models may be influenced by the difference in the severity of the
models. Thus, regarding translational evaluation, the therapeutic
paradigm may require personalization by dose titration or a
biomarker guided treatment strategy using T cell-related markers
as pharmacodynamic surrogates. For example, Treg activity
may be one such marker since our works confirmed that
VIPR2 agonism enhanced Treg activity, which confirmed others’
previous results as well that required multiple injections to
augment Treg activity in healthy subjects (Delgado et al., 2005;
Chen et al., 2008; Deng et al., 2010; Jimeno et al., 2010; Reynolds
et al., 2010; Olson et al., 2015, 2016).
While VIP and VIPR2 agonism promote Treg induction and
function, the mechanisms are not well-defined. VIPR2 expression
is either absent or minimal on resting CD4+ T cells and
Tregs, but can be upregulated by activated CD4+ T cells (LaraMarquez et al., 2001). Additionally, Tregs from lymphoid tissues
of VIPR2 deficient mice are found at lower levels and have
a diminished capacity to expand after stimulation, suggesting
a role for VIPR2 in VIP- or agonist-induced maintenance or
potentiation of Treg numbers or function. Whether that role is
limited to direct interactions by Tregs or can indirectly exert
its effects through other cell types has yet to be definitively
resolved. Indeed, we previously showed that the VIPR2 agonist,
LBT-3627 induces a 45-fold increase in GM-CSF expression
among CD4+ T cells (Olson et al., 2015), and that GM-CSFinduced tolerogenic DCs to transform naïve CD4+ T cells to
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Tregs by OX40L and Jagged1 induced signaling via OX40 and
Notch1, respectively (Gopisetty et al., 2013; Alharshawi et al.,
2017; Schutt et al., 2018). Underscoring the translational potential
of VIPR2 agonism is suggested by the demonstration that those
downstream signaling outcomes via GM-CSF have successfully
been tested in clinical trials of PD wherein sargramostimtreated patients showed increased Treg numbers and function,
augmented motor neuronal activity, and improved UPDRS
III scores (Gendelman et al., 2017). A direct mechanism is
suggested for T cells activated through CD3/CD28, whereby
VIP induced cell cycle arrest, inhibited IL-2 transcription, and
suppressed transcription factor-mediated signaling with eventual
transformation of Teff phenotypes to Treg phenotypes with
high levels of CD25, CTLA4, and FOXP3 expression as well as
potent suppressive activities (Anderson and Gonzalez-Rey, 2010).
Indeed, the first translational use of VIP for regulation of immune
conditions was tested with inhaled VIP for inflammatory
sarcoidosis which increased Treg numbers and function from T
cells in bronchoalveolar lavages (Prasse et al., 2010). Together,
these data provide strength for a therapeutic strategy of VIP and
VIP agonists as immune modulatory agents in inflammatory- or
immune-mediated conditions.
Finally, we and others have shown that specific T cell responses
are associated with PD (Baba et al., 2005; Brochard et al., 2009;
Saunders et al., 2012; Levite, 2016; Gendelman et al., 2017;
Mosley and Gendelman, 2017; Sulzer et al., 2017; Kustrimovic
et al., 2018). Previous clinical studies showed diminution
of Treg numbers or activities in PD patients compared to
non-PD controls whereby those diminutions correlated to
disorder severity (Saunders et al., 2012; Gendelman et al., 2017;
Kustrimovic et al., 2018). Moreover, exposure to modified α-Syn
has been shown to diminish Treg activity and Treg numbers
(Reynolds et al., 2008, 2009, 2010; Labrador-Garrido et al., 2014;
Schutt et al., 2018). Herein, we also demonstrated that Treg
activity was diminished in rats that overexpress α-Syn compared
to GFP controls (Figure 6), but showed no untoward effect
on numbers or proliferative function of conventional CD4+ T
cells that serve as Tresps. Treatment of α-Syn overexpressing
rats with LBT-3627 at 0.6 mg/kg slightly increased Treg activity
from the nadir attained in α-Syn expressing rats, but not to
Treg levels of controls. Rescue of Treg activity above control
levels required treatment with VIPR2 agonist concentrations
of 2–6 mg/kg. These data confirmed our previous data which
demonstrated that immunization with nitrated α-Syn diminished
Treg activity to levels significantly below naïve controls even
with concomitant increases in Treg numbers (Reynolds et al.,
2010). More recently, we found that nitrated α-Syn added during
in vitro differentiation of naïve T cells to Tregs by tolerogenic
dendritic cells significantly diminished numbers of differentiated
Tregs (Schutt et al., 2018). In previous clinical studies, we found
that Treg function levels were significantly diminished in PD
patients compared to age- and environment-matched controls
(Saunders et al., 2012; Gendelman et al., 2017). Similar to results
here, we also found that treatment with VIP at the time of
immunization with α-Syn rescued deficient Treg activity to
levels significantly above controls (Reynolds et al., 2010). More
importantly, treatment of PD patients or MPTP-intoxicated mice
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with another immune modulatory agent, GM-CSF, also rescued
Treg function and improved clinical scores as well as motor
function (Kosloski et al., 2013; Gendelman et al., 2017). Taken
together, these data indicate that that modified α-Syn regardless
of endogenous or exogenous derivation, interferes with Treg
differentiation or activation and diminishes Treg capability to
control neuroinflammation. Thus, VIP or VIPR2 agonist may
serve as a putative therapeutic to rescue deficits of differentiation
and activation and return Treg function to neuroprotective levels.
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